AARD — Aardvark Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1774857 ·
Last close
$6.60
Market Cap
$144.44M
52W High
$7.92
52W Low
$3.40
ADV30
385,770
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -22,464,000 | -21,588,000 | 98,590,000 | 62,436,000 | 11,604,000 |
| Dec 2025 | 0 | — | -18,704,000 | -17,598,000 | 117,181,000 | 47,051,000 | 10,548,000 |
| Sep 2025 | 0 | — | -17,703,000 | -16,316,000 | 133,229,000 | 39,285,000 | 10,852,000 |
| Jun 2025 | 0 | — | -15,848,000 | -14,367,000 | 147,475,000 | 25,998,000 | 10,550,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-54,172,000
Investing CF
$-49,667,000
Financing CF
$89,249,000
CapEx
$-15,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.93
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-115,918,000
Inventory
—
Receivables
—
ST Investments
$62,976,000
EBIT TTM
$-62,725,000
Pretax Income TTM
$-57,591,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -62,725,000 | -57,591,000 | 117,181,000 | 10,548,000 | — | -54,172,000 |
| Dec 2024 | 0 | -22,668,000 | -20,588,000 | 77,507,000 | 132,150,000 | — | -18,087,000 |
| Dec 2023 | 0 | -6,653,000 | -7,208,000 | 10,536,000 | 45,338,000 | — | -5,824,000 |
| Dec 2022 | 0 | -10,874,000 | -13,564,000 | 16,757,000 | 44,680,000 | — | -10,543,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.10
Max Pain — expiry 2026-08-21
max pain strike: $5.00 · spot: $6.60 · call oi: 4,755 · put oi: 518
Expected Move to 2026-08-21:
±$5.55
(84.09%) —
implied range
$1.05 –
$12.15
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KZIA | KAZIA THERAPEUTICS LTD | $144.21M | $12.62 | — |
| NKTX | Nkarta, Inc. | $149.53M | $2.09 | — |
| KRRO | Korro Bio, Inc. | $149.56M | $10.37 | — |
| EQ | Equillium, Inc. | $139.10M | $2.20 | — |
| MIST | Milestone Pharmaceuticals Inc. | $138.19M | $1.11 | — |
News headlines (Yahoo Finance, 1h cache)
Several Insiders Invested In Aardvark Therapeutics Flagging Positive News
2026-05-28 10:14 · Yahoo
Sector Update: Healthcare Stocks Decline Late Afternoon
2026-05-15 19:52 · Yahoo
Top Midday Decliners
2026-05-15 18:20 · Yahoo
FDA hold puts Aardvark Prader-Willi drug in limbo
2026-05-15 11:58 · Yahoo
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
2026-05-14 20:01 · Yahoo
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-07 12:00 · Yahoo
Discover 3 Promising Penny Stocks With Market Caps Over $100M
2026-04-17 12:05 · Yahoo
Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings
2026-03-29 20:42 · Yahoo
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
2026-03-23 20:05 · Yahoo
A Look At Aardvark Therapeutics (AARD) Valuation After The Voluntary Pause Of Its Phase 3 HERO Trial
2026-03-05 02:21 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.